A systematic review and cost-effectiveness analysis of the case for screening nulliparous women in late pregnancy using ultrasound

Smith, Gordon CS, Moraitis, Alexandros, Wastlund, David, Thornton, Jim G, Papageorghiou, Aris, Sanders, Julia, Heazell, Alexander EP, Robson, Stephen C, Sovio, Ulla, Brocklehurst, Peter and Wilson, Ed (2020) A systematic review and cost-effectiveness analysis of the case for screening nulliparous women in late pregnancy using ultrasound. Health Technology Assessment. ISSN 1366-5278 (In Press)

[img] PDF (Accepted_Manuscript) - Submitted Version
Restricted to Repository staff only until 31 December 2099.

Download (8MB) | Request a copy

Abstract

Background. Currently, pregnant women are screened using ultrasound at booking and around the middle of pregnancy. Ultrasound scans thereafter are performed for clinical indications only. Objectives. We sought to assess the case for offering universal late pregnancy ultrasound to all nulliparous women in the UK. The main questions addressed were to determine the diagnostic effectiveness of universal late pregnancy ultrasound to predict adverse outcome, and the cost effectiveness of either implementing universal ultrasound or conducting further research in this area. Design We performed diagnostic test accuracy reviews of five ultrasonic measurements in late pregnancy. We conducted cost effectiveness and value of information (VoI) analysis of screening for fetal presentation, screening for small for gestational age (SGA) fetuses and screening for large for gestational age (LGA) fetuses. We finally conducted a survey and a focus group to determine the willingness of women to participate in a future randomised trial. Data sources We searched Medline, EMBASE and the Cochrane library from inception. Review methods The protocol for the review was designed a priori and registered. Eligible studies were identified using key words with no restrictions for language or location. The risk of bias in studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. Health economic modelling employed a decision tree analysed via Monte Carlo simulation. Health outcomes were from the fetal perspective and presented as quality-adjusted life years (QALYs). Costs were from the perspective of the public sector defined as the (English) NHS and costs of special educational needs. All costs and QALYs were discounted by 3.5% per annum and the reference case time horizon was 20 years. Results Umbilical artery Doppler, cerebro-placental ratio (CPR), severe oligohydramnios, and borderline oligohydramnios were all either non-predictive or weakly predictive of the risk of neonatal morbidity (summary positive likelihood ratios [LR+] between 1 and 2) and were all weakly predictive of the risk of delivering a SGA infant (summary LR+ between 2 and 4). Suspicion of fetal macrosomia is strongly predictive of the risk of delivering a large baby but it is only weakly – albeit statistically significantly – predictive of the risk of shoulder dystocia. Very few studies blinded the result of the ultrasound scan and most studies had high risk of bias through treatment paradox, ascertainment bias or iatrogenic harm. Health economic analysis indicated that universal ultrasound for fetal presentation only may be both clinically and economically justified on the basis of existing evidence. Universal ultrasound including fetal biometry was of borderline cost-effectiveness, and sensitive to assumptions. VoI analysis indicated that future research should be focused on the cost difference between IOL and expectant management. Limitations The primary literature on the diagnostic effectiveness of ultrasound in late pregnancy is weak. VoI analysis may have underestimated the uncertainty in the literature as it was focused on the internal validity of parameters, which is quantified, whereas the greatest uncertainty may be in the external validity to the research question, which is unquantified. Conclusions Universal screening for presentation at term may be justified on the basis of current knowledge. Universal screening for fetal growth disorders cannot currently be justified. Future work We describe proof of principle randomised controlled trials which could better inform the case for screening using ultrasound in late pregnancy.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: LivePure Connector
Date Deposited: 18 Mar 2020 07:18
Last Modified: 12 Sep 2020 23:48
URI: https://ueaeprints.uea.ac.uk/id/eprint/74526
DOI:

Actions (login required)

View Item View Item